임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 2상모집 중단 (진행 중)· Lipoprotein DisorderA Study of DII235 in Adults With Elevated Lipoprotein(a)
리드: 노바티스
- 2상모집 중단 (진행 중)· Atopic DermatitisPhase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
리드: 노바티스
- 2상모집 중단 (진행 중)· Metastatic Castration Resistant Prostate Cancer (mCRPC)An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
리드: 노바티스
- 2상모집 중단 (진행 중)· Ras/MAPK Pathway Vascular Anomalies24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
협력: 노바티스
- 2상모집 중단 (진행 중)· Prostatic Cancer, Castration-ResistantA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
리드: 노바티스
- 2상모집 중단 (진행 중)· HypertensionA Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
리드: 노바티스
- 2상모집 중단 (진행 중)· Idiopathic Inflammatory MyopathiesPhase 2 Study of Rapcabtagene Autoleucel in Myositis
리드: 노바티스
- 2상모집 중단 (진행 중)· Amyotrophic Lateral Sclerosis (ALS)A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
리드: 노바티스
- 2상모집 중단 (진행 중)· Endometroid Endometrial CancerA Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisIptacopan in Patients With ANCA Associated Vasculitis
리드: 노바티스
- 2상모집 중단 (진행 중)· Metastatic Castration-Resistant Prostate Cancer (mCRPC)Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
리드: 노바티스
- 2상모집 중단 (진행 중)· Thyroid Eye DiseaseA Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
리드: 노바티스
- 2상모집 중단 (진행 중)· Prostatic NeoplasmA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
리드: 노바티스
- 2상모집 중단 (진행 중)· Breast Cancer Stage IVDetection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
협력: 노바티스
- 2상모집 중단 (진행 중)· Huntington DiseaseAn Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
리드: 노바티스
- 2상모집 중단 (진행 중)· Primary Immune Thrombocytopenia (ITP)A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
리드: 노바티스
- 2상모집 중단 (진행 중)· Metastatic Castration-Resistant Prostate Cancer (mCRPC)A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
리드: 노바티스
- 2상모집 중단 (진행 중)· Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
리드: 노바티스
- 2상모집 중단 (진행 중)· Chronic Myelogenous Leukemia - Chronic PhaseAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
리드: 노바티스
- 2상모집 중단 (진행 중)· B-cell Acute Lymphoblastic LeukemiaA Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
협력: 노바티스
- 2상모집 중단 (진행 중)· Tuberculosis, Multidrug-ResistantEfficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
협력: 노바티스, 화이자
- 2상모집 중단 (진행 중)· Neoplasm, BreastSEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
협력: 노바티스
- 2상모집 중단 (진행 중)· Breast Cancer Stage IINeoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Age-Related Macular DegenerationA Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
리드: 노바티스
- 2상모집 중단 (진행 중)· PIK3CA-related Overgrowth Spectrum (PROS)Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
리드: 노바티스
- 2상모집 중단 (진행 중)· Prostate Cancer177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Myelodysplastic SyndromesStudy of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
리드: 노바티스
- 2상모집 중단 (진행 중)· PIK3CA-related Overgrowth Spectrum (PROS)Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
리드: 노바티스
- 2상모집 중단 (진행 중)· MSI-H Colorectal CancerEfficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
협력: 노바티스
- 2상모집 중단 (진행 중)· Hormone Receptor Positive Breast CarcinomaAlpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Atrial Fibrillation (AF)Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
협력: 노바티스
- 2상모집 중단 (진행 중)· Advanced Breast CancerStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
리드: 노바티스
- 2상모집 중단 (진행 중)· NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 MutationsStudy to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
리드: 노바티스
- 2상모집 중단 (진행 중)· Mantle Cell Lymphoma RecurrentClinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
협력: 노바티스
- 2상모집 중단 (진행 중)· Chronic Myeloid LeukemiaFrontline Asciminib Combination in Chronic Phase CML
협력: 노바티스
- 2상모집 중단 (진행 중)· B-Cell Acute Lymphoblastic LeukemiaStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
리드: 노바티스
- 2상모집 중단 (진행 중)· Breast NeoplasmsTailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
협력: 노바티스
- 2상모집 중단 (진행 중)· Low Grade Serous CarcinomaRibociclib and Letrozole Treatment in Ovarian Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· FLT3-mutated Acute Myeloid LeukemiaA Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
리드: 노바티스
- 2상모집 중단 (진행 중)· Hidradenitis SuppurativaStudy of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
리드: 노바티스
- 2상모집 중단 (진행 중)· Breast CancerFACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Acute Myeloid LeukemiaStudy Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
협력: 노바티스
- 2상모집 중단 (진행 중)· Hormone-Resistant Prostate CancerTrametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Breast CancerCDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Advanced Solid Tumors Which Are cMET-dependentStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
리드: 노바티스
- 2상모집 중단 (진행 중)· Bone Marrow FibrosisRuxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
협력: 노바티스
- 2상모집 중단 (진행 중)· Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesRibociclib (LEE011) Rollover Study for Continued Access
리드: 노바티스
- 2상모집 중단 (진행 중)· Breast CancerLetrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Polycythemia Vera (PV)The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
협력: 노바티스
- 2상모집 중단 (진행 중)· Refractory Hurthle Cell Thyroid CancerSorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
협력: 노바티스
- 2상모집 중단 (진행 중)· Prostate CancerNeoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
협력: GSK, 노바티스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.